HOME >> MEDICINE >> NEWS
ARICEPT significantly improves cognition, daily living over Reminyl in Alzheimers patients

GENEVA, SWITZERLAND (4 APRIL 2002) - Results from the first head-to-head study comparing ARICEPT (donepezil HCl tablets) and Reminyl (galantamine HBr tablets) demonstrated significantly greater improvements in cognition and activities of daily living (ADLs) in mild to moderate Alzheimer's disease (AD) patients treated with ARICEPT vs. Reminyl. ARICEPT-treated patients showed significant benefit over patients receiving Reminyl as measured by the modified 13-item Alzheimer's Disease Assessment Scale-cognitive subscale (modified ADAS-cog), achieved significant improvements on the Mini-Mental State Examination (MMSE), and had significantly greater improvements in ADLs, as measured by the Disability Assessment for Dementia (DAD) scale total score. The study was primarily designed to evaluate safety and tolerability. The first-ever presentation of these data took place at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (AAT) in Geneva, Switzerland.

"By comparing two available Alzheimer's disease medications, physicians now have clinical evidence that will help them prescribe the most appropriate treatment for their patients," said study investigator Roy Jones, MD, Research Institute for the Care of the Elderly, St Martin's Hospital, Bath, United Kingdom. "This three month study is encouraging news for mild to moderate Alzheimer's disease patients currently on ARICEPT, as well as those who have yet to initiate treatment." The 12-week, multinational (United Kingdom, Finland, Norway and Germany), head-to-head, randomized open-label study was designed primarily to evaluate the safety and tolerability of ARICEPT (n= 64) and Reminyl (n= 56) in 120 patients with possible or probable mild to moderate Alzheimer's disease. The study also investigated the effects of both treatments on cognition and ADLs, such as meal preparation and finance and correspondence. Trained raters who were blinded to study medication and trial results admin
'"/>


4-Apr-2002


Page: 1 2 3 4

Related medicine news :

1. First-of-its-kind study of vascular dementia patients taking ARICEPT presented at AAGP meeting
2. Vascular dementia patients taking ARICEPT show significant treatment benefits in cognition and function
3. ARICEPT better tolerated than Exelon in patients with mild to moderate Alzheimers disease
4. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
5. Gastrointestinal disorders are associated significantly with sleepless nights
6. Landmark survey reveals asthma in children remains significantly out of control in the United States
7. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
8. Elderly cancer patients are significantly under-represented in cancer clinical trials
9. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
10. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
11. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer

Post Your Comments:
(Date:8/22/2014)... News) -- The air in American cities is getting ... Thursday. Significant progress has been made in reducing ... decades, the agency said in a news release. ... reduction in mercury from human sources such as coal-fired ... 84 percent fall in lead, which harms brain development ...
(Date:8/22/2014)... leather seat covers provided by Lseat.comare meticulously in house ... needs. Recently, the company has unveiled its latest assortment of ... wants to provide worldwide clients with more high quality items. ... a long time. According to the company’s sales manager, all ... all the new products, Chevrolet Camaro leather seat covers ...
(Date:8/22/2014)... NY (PRWEB) August 22, 2014 ... Chinese orthopedic instrument industry, some foreign and domestic ... instrument market though mergers and acquisitions. In 2012, ... maker in China-- China Kanghui Holdings for USD ... China’s largest trauma product makers-- Trauson Holdings Company ...
(Date:8/22/2014)... The graft-versus-host disease (GVHD) treatment market value will ... by 2018, at a Compound Annual Growth Rate (CAGR) ... – Opportunity Analysis and Forecasts to 2018” states that ... (6MM: the US, France, Germany, Italy, Spain and the ... (5EU), where multiple product launches will accelerate the market ...
(Date:8/22/2014)... 2014 Tug McGraw Foundation and Team McGraw ... to participate in the 39th Annual Marine Corps Marathon on ... will join forces in coaching, training and participation for the ... our nation's capital and is often referred to as the ... Corps Marathon is the largest marathon in the world that ...
Breaking Medicine News(10 mins):Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2Health News:Custom 1993-1996 Chevrolet Camaro Leather Seat Covers Now for Sale at Lseat.com 2Health News:China Orthopedic Instrument Industry 2014- Global Industry Size, Share, Trend, Growth and Forecast 2017 2Health News:Graft-Versus-Host Disease Treatment Market Worth $409.0m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Graft-Versus-Host Disease Treatment Market Worth $409.0m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Graft-Versus-Host Disease Treatment Market Worth $409.0m by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Tug McGraw Foundation and Team Red White and Blue Join to Run in Marine Corps Marathon 2Health News:Tug McGraw Foundation and Team Red White and Blue Join to Run in Marine Corps Marathon 3
(Date:8/21/2014)... BreedIT Corp., (OTCQB: BRDT) ... worldwide license holder and distributor of highly sophisticated ... today is pleased to announce the formation of ... a leading Israeli medical Cannabis breeder. ... breeds of medical Cannabis to meet the requests ...
(Date:8/21/2014)... Aug. 21, 2014  AliveCor, Inc. announced ... Administration (FDA) has granted the company clearance ... (AFib), the most common form of cardiac ... detects if patients are experiencing AFib through ... mobile phone based AliveCor® Heart Monitor, so ...
(Date:8/21/2014)... 2014   Royal Philips (NYSE: ... has received 510(k) clearance from the U.S. Food ... application for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through ... with pre-procedural, high-precision positioning to treat aortic stenosis ... is available as part of Philips IntelliSpace ...
Breaking Medicine Technology:BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 2BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 3BreedIT Ltd. and Seach Ltd. Form KanaboSeed to Develop New Medical Cannabis Varieties 4AliveCor Receives First FDA Clearance to Detect a Serious Heart Condition in an ECG on a Mobile Device 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3
Cached News: